HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.

A research team led by MSK physician-scientist Dr. Piro Lito discovered that certain inhibitors can short-circuit the out-of-control signaling caused by mutations that fuel cancer growth. Each year, ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...

Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...

Shares of Erasca ERAS soared 41.5% in a week. The massive gain was observed after the company announced encouraging early ...